微粒化力平脂治疗糖尿病合并高脂血症的疗效观察

Effects of micronized fenofibrate on serum lipid levels in diabetics with hyperlipidemia

观察微粒化力平脂在糖尿病高血脂病人中的降血脂作用。在入选的82例病人中，单纯高胆固醇血症者23例，单纯高甘油三酯血症者26例，高胆固醇血症和高甘油三酯血症混合型33例。入选时血糖为6．7±1．7mmol／L，且在整个治疗过程中保持稳定，服药前的TC、TG分别为5．8±1．4mmol／L、3．2±3．lmmol／L。服用方法每晚睡前200mg，一次顿服。在服药第四周，降至4．9±1．2mmol／L和1．7士1．lmmol／L，下降幅度分别为15．5土15．0％和46．9士29．0％，至第八周进一步降低至4．4土1．0mmol／L、1．5士0．8mmol／L，下降幅度分别为24．1士16．8％和53．1士26．6％，TG下降幅度皆明显高于TC下降幅度，说明此药对TG作用更为明显。在治疗期间，LDL－C水平则逐渐升高，分别为1．5士0·6mmol／L、l.6士0.6mmol／L和1.7士0．6mmol／L。ApoA和ApoB在整个治疗期间无明显变化，未见明显副作用。

To investigate the effects of fenofibrate on serum total cholesterol(TC)and triglycerides(TG)in diabetic patients with hyperlipidemia. 82 NIDDM cases were selected with hyper-cholesterolemia in23, hyper-triglyceridemia in 26,and both high in 33. Fenofibrate 200mg was given every night foratotal of 8weeks. Results: Basal mean blood glucose level of all subjects was 6. 7±1. 7mmol/L and it remained unchanged during the trial. The serum TC and TG were 5.8±1. 4mmol/L, 3. 2±3. lmmol/L at the beginning of the study and decreased to 4. 9±1. 2mmol/L(15. 5±15. 0% ), 1. 7±1. lmmol/L (46. 9±29. 0 % )and 4. 4±1. 0mmol/L(24. 1±16. 8% ), 1.5±0.8mmol/L(53. 1±26. 6%)at the end of 4 and 8 weeks respectively. The decreasing level of TG was much greater than that of TC. Decreasing tendency of LDL-Cand increasing trend of HDL-C were observed. ApoA and ApoB remained stable and no obvious adverse effects of the drug in any subjects were found during the whole trial. Micronized fenofibrate could significantly and safely decrease serum lipids level in diabetics with hyperlipidemias.